Structure via PubChem · Public domain (PubChem)
alogliptin
Sign in to saveAlso known as Nesina®, SYR-322, Vipidia®, Alogliptinum, Alogliptine, Alogliptina
Alogliptin, sold under the brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.
In the Vinony graph
Vinony's link graph records 147 inbound references to alogliptin, and connects out to metformin, anti-diabetic medication and ertugliflozin.
It is catalogued under topics including Benzonitriles, Chemical articles with multiple CAS registry numbers and Chemical pages without DrugBank identifier.
Vinony links it to 14 Wikipedia language editions.
Chemical data
- Formula
- C18H21N5O2
- Molecular weight
- 339.4 g/mol
- IUPAC name
- 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
- SMILES
- CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
- InChIKey
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N
- XLogP
- 0.6
- Polar surface area
- 93.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2013
- Admin. routes
- oral
- Indications
- diabetes mellitus, type 2 diabetes mellitus
via ChEMBL · EBI
Research
680 papers- Alogliptin.2006
- Alogliptin.2012
- Alogliptin.2026
- Alogliptin-Associated Angioedema: Case Report and Review of the Literature.American journal of therapeutics · 2022
- [Alogliptin].Nihon rinsho. Japanese journal of clinical medicine · 2011
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 339.17
- Has use
- medication
Show 9 more facts
- chemical formula
- C₁₈H₂₁N₅O₂
- isomeric SMILES
- CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
- canonical SMILES
- CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
- World Health Organisation international non-proprietary name
- alogliptin
- Commons category
- Alogliptin
- defined daily dose
- 25
- subject has role
- incretins
- physically interacts with
- Dipeptidyl peptidase 4
- melting point
- 181
Sources (6)
via Wikidata · CC0
~4 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Side effects
- Market access
- References
- External links
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 454952697 | image = Alogliptin.svg | image_class = skin-invert-image | alt =
| pronounce = | tradename = Nesina, VipidiaKazano, Vipidomet (with metformin)Oseni, Incresync (with pioglitazone) | Drugs.com = | MedlinePlus = a613026 | licence_EU = yes | DailyMedID = Alogliptin | licence_US = | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_US = B | pregnancy_US_comment = | pregnancy_category = | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BH04
Excerpted from Wikipedia’s “alogliptin” article, available under the CC BY-SA 4.0 licence.